Chronic Lymphocytic Leukemia

• CLINICAL_TRIALS trial_result · 2020-10-14
  Clinical Trial Update: Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia. [Phase 2]

  Phase 2 trial assessing frontline fludarabine, cyclophosphamide, and ofatumumab chemoimmunotherapy in young patients with B-cell lymphoid le…

• CLINICAL_TRIALS trial_result · 2020-10-08
  Clinical Trial Update: A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL [Phase 2]

  Phase II clinical trial evaluating the combination of ibrutinib and short-course fludarabine in treatment-naive chronic lymphocytic leukemia…

• CLINICAL_TRIALS trial_result · 2020-09-25
  Clinical Trial Update: Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]

  A Phase 2 trial evaluating the efficacy and safety of zanubrutinib in relapsed or refractory chronic lymphocytic leukemia and small lymphocy…

• CLINICAL_TRIALS trial_result · 2020-09-23
  Clinical Trial Update: Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies [Phase 2]

  Phase 2 study evaluating entospletinib in adults with relapsed or refractory hematologic malignancies; study terminated with posted results.

• CLINICAL_TRIALS trial_result · 2020-09-10
  Clinical Trial Update: Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases [Phase 2]

  Phase 2 trial evaluating myeloablative umbilical cord blood transplantation in various hematological diseases has completed with results pos…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2020-08-26
  Clinical Trial Update: Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig [Phase 2, Phase 3]

  Phase 2/3 trial update evaluating humoral immunodeficiency in chronic lymphocytic leukemia (CLL) and therapy with subcutaneous immunoglobuli…

• CLINICAL_TRIALS trial_result · 2020-08-20
  Clinical Trial Update: BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) [Phase 1]

  Phase 1 dose-escalation trial of BI836826 in relapsed chronic lymphocytic leukemia (CLL) completed; results posted.

• CLINICAL_TRIALS trial_result · 2020-08-13
  Clinical Trial Update: UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 1]

  Phase 1 clinical trial of UC-961 (cirmtuzumab) in relapsed or refractory chronic lymphocytic leukemia has completed with results posted.

• CLINICAL_TRIALS trial_result · 2020-08-12
  Clinical Trial Update: IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT [Phase 1, Phase 2]

  Clinical trial update on an IL-15 super agonist ALT-803 for relapse of hematologic malignancies after allogeneic stem cell transplant, compl…

• FDA approval · 2020-08-07
  FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)

  FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.

• CLINICAL_TRIALS trial_result · 2020-07-24
  Clinical Trial Update: Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib [Phase 1]

  Phase 1 trial evaluating intravenous BI 836826 in combination with ibrutinib in relapsed/refractory chronic lymphocytic leukemia after prior…

• CLINICAL_TRIALS trial_result · 2020-07-01
  Clinical Trial Update: Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 2]

  Phase 2 trial evaluating tirabrutinib and idelalisib with/without obinutuzumab in relapsed/refractory chronic lymphocytic leukemia has compl…

• CLINICAL_TRIALS trial_result · 2020-06-23
  Clinical Trial Update: Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

  Phase 1/2 clinical trial evaluating Imprime PGG with Alemtuzumab and Rituximab in high-risk chronic lymphocytic leukemia has completed with …

• CLINICAL_TRIALS trial_result · 2020-06-23
  Clinical Trial Update: A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL [Phase 1]

  This report summarizes results from a Phase I/Ib safety and preliminary efficacy study of the PI3K-delta inhibitor TGR-1202 in combination w…

• CLINICAL_TRIALS trial_result · 2020-06-16
  Clinical Trial Update: Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia [Phase 1, Phase 2]

  Clinical trial update for lenalidomide and AT-101 in relapsed B-cell chronic lymphocytic leukemia (Phase 1/2) has terminated; results posted…

• CLINICAL_TRIALS trial_result · 2020-06-11
  Clinical Trial Update: Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO) [Phase 2]

  Phase 2 clinical trial update evaluating a sequential regimen of bendamustine debulking followed by ofatumumab and ibrutinib in chronic lymp…

• CLINICAL_TRIALS trial_result · 2020-06-02
  Clinical Trial Update: Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies [Phase 2]

  Phase 2 trial of Entospletinib plus Idelalisib in adults with relapsed or refractory hematologic malignancies was terminated; results posted…

• CLINICAL_TRIALS trial_result · 2020-05-26
  Clinical Trial Update: Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients [Phase 2]

  Phase 2 clinical trial evaluating lirilumab in combination with rituximab for relapsed/refractory or high-risk untreated chronic lymphocytic…

• CLINICAL_TRIALS trial_result · 2020-05-15
  Clinical Trial Update: A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia [Phase 2]

  Phase II study evaluating ibrutinib in combination with FCR (fludarabine, cyclophosphamide, rituximab) in previously untreated, younger pati…

• FDA approval · 2020-05-05
  FDA Approved: RITUXAN HYCELA — Supplemental Application (Genentech, Inc.)

  The FDA approved a supplemental application for Rituxan HYCELA (rituximab and hyaluronidase) from Genentech, expanding its approval through …

• CLINICAL_TRIALS trial_result · 2020-05-04
  Clinical Trial Update: A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) [Phase 3]

  A Phase 3 trial evaluating venetoclax monotherapy in relapsed/refractory chronic lymphocytic leukemia has completed with results posted in 2…

• FDA approval · 2020-04-21
  FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)

  FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.

• CLINICAL_TRIALS trial_result · 2020-04-13
  Clinical Trial Update: Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) [Phase 1]

  Phase 1 study of ADCT-402 in relapsed or refractory B-cell lineage non-Hodgkin lymphoma completed; results posted in 2020.

• CLINICAL_TRIALS trial_result · 2020-04-06
  Clinical Trial Update: Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia [Phase 3]

  Phase 3 trial evaluating early versus delayed fludarabine and rituximab in previously untreated chronic lymphocytic leukemia; study terminat…

• CLINICAL_TRIALS trial_result · 2020-04-06
  Clinical Trial Update: Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia [Phase 2]

  Phase 2 clinical trial update of fludarabine in treating chronic lymphocytic leukemia.